Guangdong Lifestrong Pharmacy Co. Ltd.

301111 · SHE · Healthcare / Drug Manufacturers - Specialty & Generic

17.15CNY-0.25 (-1.44%)

Price History

Full chart

Market Stats

Previous Close17.40

Open17.40

Day Range17.06 – 17.88

52-Week Range15.05 – 31.30

Volume5.37M

Market Cap3.41B

P/E (TTM)710.00

Forward P/E0.00

EPS0.03

Dividend Yield0.23%

Beta0.98

50-Day Avg20.86

200-Day Avg21.95

About

Guangdong Lifestrong Pharmacy Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products. It operates through Medical Services and Health Management; and Health Consumer Products segments. The company produces tablets, hard capsules, injections, and pills, and other related products. It also offers respiratory, pediatric, gynecology, urinary, and nutrition and healthcare category products. Guangdong Lifestrong Pharmacy Co., Ltd. was founded in 1951 and is headquartered in Shantou, China.

Company Details

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CEOMr. Ou Xiantao
Employees578
HeadquartersNo. 08, Block 16th, Shantou, China, 515064, China
Websitehttps://www.wnqzy.com.cn

Leadership

Mr. Ou XiantaoCEO & Chairman of the Board · b. 1961
Mr. Zeqing OuVP & Director · b. 1989
Mr. Xiuyan ChenVP, CFO, Board Secretary & Director · b. 1975
Xing Yu ChenAccounting Supervisor

Financials

Income Statement

Currency: CNY	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	191.59M	290.49M	316.58M	340.96M	349.79M	283.34M	292.40M	278.64M	314.64M
Growth (%)	-	+51.62%	+8.98%	+7.70%	+2.59%	-19.00%	+3.20%	-4.71%	+12.92%
Cost of Revenue	87.42M	89.79M	87.58M	114.80M	107.53M	92.74M	94.55M	89.00M	123.78M
Gross Profit	104.17M	200.70M	229.00M	226.15M	242.26M	190.60M	197.85M	189.64M	190.86M
Gross Margin	54.37%	69.09%	72.34%	66.33%	69.26%	67.27%	67.66%	68.06%	60.66%
Operating Expense	65.70M	126.14M	144.85M	153.46M	172.00M	147.49M	156.67M	188.76M	208.91M
Operating Income	38.47M	74.56M	84.15M	72.69M	70.26M	43.10M	41.18M	884.10K	-18.05M
Operating Margin	20.08%	25.67%	26.58%	21.32%	20.09%	15.21%	14.08%	0.32%	-5.74%
EBITDA	75.29M	86.59M	89.01M	84.01M	81.02M	46.09M	48.44M	13.09M	11.64M
EBITDA Margin	39.30%	29.81%	28.12%	24.64%	23.16%	16.27%	16.57%	4.70%	3.70%
Net Income	32.76M	63.60M	66.63M	62.52M	57.18M	33.42M	33.50M	4.16M	-4.49M
Net Income Margin	17.10%	21.89%	21.05%	18.34%	16.35%	11.79%	11.46%	1.49%	-1.43%
R&D	6.92M	7.04M	7.82M	10.55M	10.87M	9.16M	8.44M	8.41M	8.49M
R&D as % of Total Revenue	3.61%	2.42%	2.47%	3.09%	3.11%	3.23%	2.89%	3.02%	2.70%
Interest Expense	8.95M	743.73K	42.67K	146.69K	198.98K	27.80K	398.52K	2.52M	3.06M
Interest Expense % of Total Revenue	4.67%	0.26%	0.01%	0.04%	0.06%	0.01%	0.14%	0.91%	0.97%

Balance Sheet

Currency: CNY	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	280.91M	297.61M	325.26M	383.78M	826.20M	857.06M	855.54M	933.17M	894.13M
Total Liabilities	114.55M	67.64M	53.57M	60.37M	75.34M	98.39M	77.33M	166.42M	142.91M
Total Equity	166.37M	229.97M	271.68M	323.41M	750.85M	758.67M	776.17M	764.34M	750.69M
Cash	94.99M	93.99M	74.20M	108.13M	485.35M	179.21M	131.11M	159.10M	143.14M
Total Debt	46.70M	-	-	-	1.09M	158.90K	13.95M	72.15M	-
Net Debt	-48.29M	-93.99M	-74.20M	-108.13M	-484.26M	-179.05M	-117.16M	-86.95M	-

Cash Flow

Currency: CNY	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	7.04M	41.40M	48.70M	90.90M	71.63M	69.88M	-12.80M	3.21M	10.58M
Investing Cash Flow	275.41M	5.07M	-74.22M	-70.28M	-76.86M	-304.67M	-19.30M	72.13M	-
Financing Cash Flow	-206.85M	-47.46M	-30.00M	-14.64M	379.06M	-35.76M	-17.09M	-14.79M	-
Capital Expenditure	1.65M	1.35M	12.83M	46.10M	3.09M	5.54M	38.61M	37.90M	9.78M
Free Cash Flow	5.40M	40.05M	35.88M	44.80M	68.54M	64.34M	-51.41M	-34.69M	803.35K
Dividends Paid	47.66M	764.65K	30.00M	10.80M	-	25.60M	16.00M	16.00M	8.00M
FCF to OCF	76.61%	96.74%	73.67%	49.29%	95.68%	92.07%	401.67%	-1081.08%	7.59%
Dividend Paid to FCF	883.26%	1.91%	83.62%	24.11%	-	39.79%	-31.12%	-46.13%	995.83%

Earnings

Report Date	Dec 31, 2021	Mar 31, 2022	Jun 30, 2022	Sep 30, 2022	Dec 31, 2022	Mar 31, 2023	Jun 30, 2023	Sep 30, 2023	Dec 31, 2023	Mar 31, 2024	Jun 30, 2024	Sep 30, 2024	Dec 31, 2024	Mar 31, 2025	Jun 30, 2025	Sep 30, 2025	Dec 31, 2025	Mar 31, 2026	Jun 30, 2026
EPS Estimate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EPS Actual	0.07	0.08	0.08	0.04	0.01	0.09	0.06	0.04	0.02	0.07	0.02	-0.01	-0.06	-0.02	-0.02	-0.01	0.02	-0.02	0.04
Surprise	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Timing	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Key Statistics & Ratios

Market Cap3.41B

Enterprise Value3.31B

Trailing P/E710.00

Forward P/E0.00

Price / Sales11.19

Price / Book4.96

EPS0.03

Book Value4.66

Revenue (TTM)304.63M

Gross Profit (TTM)174.23M

EBITDA3.72M

Profit Margin1.95%

Operating Margin5.96%

Return on Equity0.41%

Return on Assets-0.34%

Shares Outstanding160.00M

Shares Float90.20M

Beta0.98

Dividend Yield0.23%

Dividend Rate0.05

Payout Ratio135.14%

Dividends

20261×

0.05Jun 11, 2026

20251×

0.05May 27, 2025

20241×

0.10May 23, 2024

20231×

0.10Jun 1, 2023

20221×

0.16May 26, 2022